English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Aim:  To evaluate the prognostic value of circulating VE-catherinfor cumulative survivalin patients with ischemic chronic heart failure (CHF).   Methods:  A total of 154 patients withischemic symptomatic moderate-to-severe CHF were enrolled in the study on discharge from the hospital. Observation period was up to 3 years. Blood samples for biomarkers measurements were collected. ELISA method for measurements of circulating level of VE-catherin was used. Concentrations of VEcatherinfor cumulative survival cases due to advanced CHF were tested. Additionally, all-cause mortality, and CHFrelated death were examined.   Results:  During a median follow-up of 2.18 years, 21 participants died and 106 subjects were hospitalized repetitively. Medians of circulating levels of VE-catherin in survived and died patient cohort were 0.63 ng/ml (95% confidence interval [CI] = 0.55-0.64 ng/ml) and 1.03 ng/ml (95% CI = 0.97-1.07 ng/ml) (P 0.755 ng/ml) and low (u003c0.755 ng/ml) concentrations of VE-catherin. Circulating VE-catherin independently predicted all-cause mortality (OR = 1.27; 95% CI = 1.081.59; P = 0.002), CHF-related death (OR = 1.16; 95% CI 1.021.50; P u003c 0.001), and also CHF-related rehospitalisation (OR = 1.12; 95% CI = 1.07  1.25; Pu003c0.001) within 3 years of observation period.   Conclusion:  Increased circulating VE-catherinassociates with increased 3-year CHF-related death, all-cause mortality, and risk for recurrent hospitalization due to CHF.  J MEDICINE July 2015; 16 (2) : 73-78

Predictive Value of Circulatingve-catherin in Coronary Artery Disease Patients with Symptomatic Moderate to Severe Chronic Heart Failure